Q3 2017 Earnings Forecast for CSPC Pharmaceutical Group Ltd (CHPTY) Issued By Jefferies Group

CSPC Pharmaceutical Group Ltd (OTCMKTS:CHPTY) – Stock analysts at Jefferies Group lifted their Q3 2017 earnings estimates for shares of CSPC Pharmaceutical Group in a research report issued to clients and investors on Wednesday, Zacks Investment Research reports. Jefferies Group analyst E. Huang now expects that the company will post earnings per share of $0.77 for the quarter, up from their prior estimate of $0.74. Jefferies Group also issued estimates for CSPC Pharmaceutical Group’s Q4 2017 earnings at $0.77 EPS, FY2017 earnings at $2.88 EPS, FY2018 earnings at $3.78 EPS and FY2019 earnings at $4.87 EPS.

Separately, Zacks Investment Research cut shares of CSPC Pharmaceutical Group from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th.

CSPC Pharmaceutical Group (OTCMKTS:CHPTY) remained flat at $$101.08 during mid-day trading on Friday. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 0.02. The company has a market cap of $12,620.00, a P/E ratio of 39.79, a P/E/G ratio of 1.21 and a beta of 1.31. CSPC Pharmaceutical Group has a 52 week low of $51.99 and a 52 week high of $104.77.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2017/12/04/jefferies-group-comments-on-cspc-pharmaceutical-group-ltd-s-q3-2017-earnings-chpty.html.

CSPC Pharmaceutical Group Company Profile

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).

Get a free copy of the Zacks research report on CSPC Pharmaceutical Group (CHPTY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply